Failure to improve the effect of thrombolysis by memantine in a rat embolic stroke model

REFERENCES

• Chen SD, Lee JM, Yang DI, et al. Combination therapy for ischemic stroke: Potential of neuroprotectants plus thrombolytics. Am J Cardiovasc Drugs 2002; 2:303–313
   PubMedGoogle Scholar
• Sereghy T, Overgaard K, Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in ebmolic stroke in rats. Stroke 1993; 24: 1702–1708
   PubMed Web of Science ®Google Scholar
• Meden P, Overgaard K, Sereghy T, et al. Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sci 1993; 119: 209–216
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Q, Miyashita H, et al. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. J Neurosurg 2000; 92: 841–847
   PubMed Web of Science ®Google Scholar
• Bowes MP, Rothlein R, Fagan SC, et al. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995; 45: 815–819
   PubMed Web of Science ®Google Scholar
• Andersen M, Overgaard K, Meden P, et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999; 30: 1464–1471
   PubMed Web of Science ®Google Scholar
• Green AR, Ashwood T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: Experimental and clinical studies with NXY-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord 2005; 4: 109–118
   PubMedGoogle Scholar
• Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: Neuroprotective effects when used alone or in combination with urokinase. Exp Neurol 2000; 161: 733–739
   PubMed Web of Science ®Google Scholar
• Lekieffre D, Benavides J, Scatton B, et al. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 1997; 776: 88–95
   PubMed Web of Science ®Google Scholar
• Christou I, Alexandroy AV, Burgin WS, et al. Timing of recanalization after tissue plasminogen activator therapy deter-mined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 2000; 31: 1812–1816
   PubMed Web of Science ®Google Scholar
• Roether J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke 6 hours. Stroke 2002; 33: 2438–2445
   PubMed Web of Science ®Google Scholar
• Schueler OG, Plesnila N, Otto D, et al. Early thrombolysis inhibits pen-infarct depolarizations in embolic MCA occlusion. Neuroreport 2001; 12: 3943–3946
   PubMed Web of Science ®Google Scholar
• Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993; 33: 403–407
   PubMed Web of Science ®Google Scholar
• Gorgulu A, Kins T, Cobanoglu S, et al. Reduction of edema and infarction by memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir (Wien) 2000; 142: 1287–1292
   PubMed Web of Science ®Google Scholar
• Zhang RL, Chopp M, Zhang ZG, et al. A rat model of focal embolic cerebral ischemia. Brain Res 1997; 766: 83–92
   PubMed Web of Science ®Google Scholar
• Back T, Ginsberg MD, Dietrich WD, et al. Induction of spreading depression in the ischemic hemisphere following experimental middle cerebral artery occlusion: Effect on infarct morphology. J Cereb Blood Flow Metab 1996; 16: 202–213
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Zhang RL, et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32: 2926–2931
   PubMed Web of Science ®Google Scholar
• Yasuda T, Gold HK, Leinbach RC, et al. Kistrin, a polypeptide platelet GPIlb/Illa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991; 83: 1038–1047
   PubMed Web of Science ®Google Scholar
• del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT investi-gators. Prolyse in Acute Cerebral Thromboembol ism. Stroke 1998; 29: 4–11
   PubMed Web of Science ®Google Scholar
• von Kummer R, Holle R, Rosin L, et al. Does arterial recanalization improve outcome in carotid territory stroke? Stroke 1995; 26: 581-487
   PubMed Web of Science ®Google Scholar
• Seif eN, Peruche B, Rossberg C, et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990; 185: 19–24
   PubMed Web of Science ®Google Scholar
• Block F, Schwarz M. Memantine reduces functional and morpho-logical consequences induced by global ischemia in rats. Neurosci Lett 1996; 208: 41–44
   PubMed Web of Science ®Google Scholar
• Stieg PE, Sathi S, Warach S, et al. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photo-thrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol 1999; 375: 115–120
   PubMed Web of Science ®Google Scholar
• Dogan A, Eras MA, Rao VL, et al. Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Acta Neurochir (Wien) 1999; 141: 1107–1113
   PubMed Web of Science ®Google Scholar
• Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: Facts and fancies—the need for new approaches. Cerebrovasc Dis 2004; 17 (Suppl. 1): 153-166
   Google Scholar